Breaking: EU Medicines Agency announced “EMA Multi-Stakeholder Workshop on Psychedelics – Towards an EU Regulatory Framework,” 16-17 April 2024 in Amsterdam. PAREA is proud to have advocated for this workshop. See our news release here: tinyurl.com/PAREA-news-wor…

BREAKING: MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics We take a closer look at MAPS PBC’s Series A, rebrand to Lykos, and what this might tell us about an organisation that so desperately wants to do things differently. psychedelicalpha.com/news/maps-pbc-…

Dr. Hannu Alho, our chief investigator for CLA-PSY-201, was recently interviewed on Good Morning Finland on MTV Katsomo about our current phase IIb #psilocybin research study for #alcoholusedisorder.

Design + KOL engagement + regulatory engagement / approvals / inspections + strong participant recruitment + seasoned clinical team = multiple data read outs in 2024 ... with strong phase 2b data we'll rinse & repeat for phase 3

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study nature.com/articles/s4159…

Encouraging data from a recent Scientific Reports study demonstrates #psilocybin-assisted therapy induces neural reactivity changes and improved emotional regulation in #alcoholusedisorder patients. See the article here: nature.com/articles/s4159…

We extend our heartfelt congratulations to the two Co-Chairs of our MEP Action Group for the Medical Use of Psychedelics - Sara Cerdas and Tilly Metz - for being recognized among the most influential MEPs in health 👏👏👏 bit.ly/49V8PCM Tilly Metz MEP Sara Cerdas

What the professor ordered: The results of Clairvoyant's Phase 2b #psilocybin therapy for #AUD will shine a light on the efficacy of the second dose. Top line results expected Q3/24. See the CNN article with @ProfDavidNutton on psilocybin here: cnn.com/2022/06/11/hea…

Clairvoyant is on target to achieve first global commercialization of clinically validated psilocybin in 2025 for alcohol use disorder. Read the The New York Times article on alcohol abuse here: tinyurl.com/muf326sf #psilocybin #alcoholusedisorder #psychedelicstherapy

Clairvoyant Therapeutics is pleased to announce that we are on target to potentially become the first to commercialize psilocybin treatment with clinical validity in 2025. Press Release: tinyurl.com/wr96ey6f #biotech #psychedelics #psychedelictreatments #psilocybintherapy

#LendAHand to help researchers at The B.R.A.I.N. Lab evaluate the safety & efficacy of psilocybin-assisted psychotherapy for adults with alcohol use disorder: vchri.ca/research-study… #ParticipateInResearch #YesToResearch UBC Department of Psychiatry christian schutz Clairvoyantrx Djavad Mowafaghian Centre for Brain Health

Clairvoyant Therapeutics celebrates a huge milestone this week and announces completion of recruitment for our Phase IIb psilocybin trial for treatment of alcohol use disorder. #psilocybin #alcoholusedisorder #psychedelics #therapy

Nice to see UK Parliament highlight evidence that high doses of psilocybin and psychotherapy can help those suffering with alcohol use disorder. Read the article here: tinyurl.com/3dp95atp

Clairvoyant Therapeutics is excited to announce the completion of randomization and celebrates the enrollment of the final participant in our Phase IIb psilocybin trial for treatment of alcohol use disorder. #psilocybintherapy #psychedelics #randomization #clinicaltrials #AUD

A recent study from Denmark found that a 25 mg single dose of psilocybin therapy reduced heavy drinking days and decreased drinks per day for participants with alcohol use disorder. #psilocybin #alcoholusedisorder #psychedelics #therapy Link to article: researchsquare.com/article/rs-494…